In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Emma Gauthier *Laboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.
Matthieu Pisani *Laboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.
Maxime BourLaboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.
Mélanie GrosjeanRD-Biotech Company, Besançon, France.
Patrick PlésiatLaboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.ORCID 0000-0001-7381-5671 Shahriar SafariUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019-UMR 9017, Center for Infection and Immunity of Lille (CIIL), Lille, France.
Ruben C HartkoornUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019-UMR 9017, Center for Infection and Immunity of Lille (CIIL), Lille, France.ORCID 0000-0001-7315-1553 Léa SouroLaboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.
Emma PrétotLaboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.ORCID 0009-0007-4846-4639 Katy JeannotLaboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.ORCID 0000-0002-4634-8550 Funding
Sante publique France
6 · The paper itselfAbstract
Cefiderocol exhibits excellent
Indexed as
Anti-Bacterial AgentsCephalosporinsPseudomonas aeruginosaBacterial Proteinsbeta-LactamasesCefiderocolFranceHumansMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCefiderocolCephalosporinsantimicrobial resistancecefiderocolPseudomonas aeruginosa
Identifiers
PMID42429933
PMCPMC13435742
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390